All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu

Links:

Dr. John Cush RheumNow ( View Tweet)
Looking at those results (distributed evenly each side of 'maybe a little') it seems we're collectively uncertain right now about what JAK1 selectivity really means in practice. Hopefully we get stronger clinical insights (toxicity/efficacy) in coming years! #EULAR2021 @RheumNow https://t.co/jFhVGqpOnb

Links:

David Liew drdavidliew ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Richard Conway RichardPAConway ( View Tweet)
Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
Janet Pope Janetbirdope ( View Tweet)

After 1st JAKi in RA would you use a 2nd #Jaki? @eular_org

Janet Pope Janetbirdope ( View Tweet)

JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr

Janet Pope Janetbirdope ( View Tweet)

Do you think that JAK1 selectivity matters in rheumatological clinical practice? #EULAR2021 @RheumNow

David Liew drdavidliew ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×